Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer
Journal of Pathology and Translational Medicine
;
: 244-252, 2019.
Article
in English
| WPRIM
| ID: wpr-766027
ABSTRACT
BACKGROUND:
Ovarian epithelial cancer (OEC) is the second-most common gynecologic malignancy. CD109 expression is elevated in human tumor cell lines and carcinomas. A previous study showed that CD109 expression is elevated in human tumor cell lines and CD109 plays a role in cancer progression. Therefore, this study aimed to determine whether CD109 is expressed in OEC and can be useful in predicting the prognosis.METHODS:
Immunohistochemical staining for CD109 and reverse transcription-quantitative polymerase chain reaction was performed. Then we compared CD109 expression and chemoresistance, overall survival, and recurrence-free survival of OEC patients. Chemoresistance was evaluated by dividing into good-response group and poor-response group by the time to recurrence after chemotherapy.RESULTS:
CD109 expression was associated with overall survival (p = .020), but not recurrence-free survival (p = .290). CD109 expression was not an independent risk factor for overall survival due to its reliability (hazard ratio, 1.58; p = .160; 95% confidence interval, 0.82 to 3.05), although we found that CD109 positivity was related to chemoresistance. The poor-response group showed higher rates of CD109 expression than the good-response group (93.8% vs 66.7%, p = .047). Also, the CD109 mRNA expression level was 2.88 times higher in the poor-response group as compared to the good-response group (p = .001).CONCLUSIONS:
Examining the CD109 expression in patients with OEC may be helpful in predicting survival and chemotherapeutic effect.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Recurrence
/
RNA, Messenger
/
Polymerase Chain Reaction
/
Risk Factors
/
Cell Line, Tumor
/
Drug Therapy
Type of study:
Etiology study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Journal of Pathology and Translational Medicine
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS